Onset of severe perianal disease in Crohnʼs disease under treatment with infliximab

Tursi, Antonio; Papa, Alfredo; Maiorano, Michele

doi:10.1002/ibd.21292

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Spain in which 30% had active fistulizing disease, with 60% having previous infliximab exposure, resulted in complete response in 50% after 4 weeks and 87.5% maintained remission after 48 weeks (95). One case report of a patient who developed a fistula while taking infliximab documented complete closure with seton placement plus adalimumab (96).…”

Section: Pamentioning

confidence: 99%

Diagnosis and Treatment of Perianal Crohn Disease

Zoeten

Pasternak²,

Mattei³

et al. 2013

J. pediatr. gastroenterol. nutr.

137

View full text Add to dashboard Cite

Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract that includes both Crohn disease (CD) and ulcerative colitis. Abdominal pain, rectal bleeding, diarrhea, and weight loss characterize both CD and ulcerative colitis. The incidence of IBD in the United States is 70 to 150 cases per 100,000 individuals and, as with other autoimmune diseases, is on the rise. CD can affect any part of the gastrointestinal tract from the mouth to the anus and frequently will include perianal disease. The first description connecting regional enteritis with perianal disease was by Bissell et al in 1934, and since that time perianal disease has become a recognized entity and an important consideration in the diagnosis and treatment of CD. Perianal Crohn disease (PCD) is defined as inflammation at or near the anus, including tags, fissures, fistulae, abscesses, or stenosis. The symptoms of PCD include pain, itching, bleeding, purulent discharge, and incontinence of stool. In this report, we review and discuss the etiology, diagnosis, evaluation, and treatment of PCD.

show abstract

Section: Pamentioning

confidence: 99%

Diagnosis and Treatment of Perianal Crohn Disease

Zoeten

Pasternak²,

Mattei³

et al. 2013

J. pediatr. gastroenterol. nutr.

137

View full text Add to dashboard Cite

show abstract

“…The introduction of biological therapy for perianal CD has added an additional factor which might influence the ability to achieve stoma closure , but data on this topic are still limited. Therefore, the aim of the present study was to observe the fate of patients having a planned temporary faecal diversion for perianal CD and to identify any potential factors which might influence closure of the diverting stoma.…”

Section: Introductionmentioning

confidence: 99%